Modulating charge density to produce improvements in the characteristics of spray-dried proteins

Inactive Publication Date: 2005-06-09
NOVARTIS FARMA
View PDF8 Cites 35 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012] It is yet still another object of the invention to provide such a method wherein increasing the absolute net charge is effected by including the optional excipie

Problems solved by technology

Despite these initially encouraging results, however, the role of inhalation therapy in the health care field has not grown as expected over recent years, in part due to a set of problems unique to the development of inhalable drug formulations.
In particular, dry powder formulations for pulmonary delivery, while offering unique advantages over liquid dosage forms and propellant-driven formulations, are often prone to agglomeration and low flowability phenomena.
These and other phenomena considerably diminish the efficiency of delivery and the efficacy of dry powder-based inhalation therapies.
Each technique, however, can produce particles that exhibit unsatisfactory properties such as agglomeration, low flowability, and so forth.
While spray drying has been long employed in the food an

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulating charge density to produce improvements in the characteristics of spray-dried proteins
  • Modulating charge density to produce improvements in the characteristics of spray-dried proteins
  • Modulating charge density to produce improvements in the characteristics of spray-dried proteins

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0115] A human growth hormone (hGH) formulation for pulmonary delivery was prepared. Methionyl-human growth hormone (Met-hGH, pI 5.2), obtained from BreSagen Limited (Adelaide, SA) was mixed at a concentration of 7 mg / mL (70% w / w) with trileucine (pI 5.9, Bachem Calif. Inc., Torrance, Calif.) at concentrations of 1.5 and 3 mg / mL, in separate solutions. Each solution was then divided and one solution was adjusted to a pH of 3.6 with an acid while the other was adjusted to a pH of 7.8 with a base. Individually, the solutions were spray dried to form particles using a Buchi 190 laboratory scale drier (Buchi, Switzerland) under the following conditions: feed rate: 5 ml / min; outlet temperature: 60° C.; and atomization pressure: 80 psi (0.55 MPa). The dispersibility of these Met-hGH particles are listed in Table 3 below:

TABLE 3Emitted Dose (ED) Results for Spray-Dried Met-hGH Formulationsat Two pH and Two Trileucine Levels15% trilecuine30% trileucinepH 3.692% ED88% EDpH 7.875% ED73

example 2

[0117] An interferon beta formulation for pulmonary delivery was prepared. Interferon beta, obtained from Biogen, Inc. (Cambridge, Mass.), at a concentration of 1 mg / mL was mixed with raffinose at a concentration of 9 mg / mL and titrated to pH 4.0 with HCl. A pH of 4.0 lies 2 to 2.5 pH units below the pI of the fully glycosylated interferon beta. The solution was spray dried to form particles using a Buchi 190 laboratory scale drier (Buchi, Switzerland) under the following conditions: feed rate: 5 ml / min; outlet temperature: 65° C.; and atomization pressure: 100 psi (0.69 MPa). The ED for this formulation was 67% (±8%). The ED for formulations at a higher pH (e.g., pH 5) could not be determined due to the presence of protein aggregates.

example 3

[0118] An interleukin-4 receptor formulation for pulmonary delivery was prepared. Soluble interleukin-4 receptor, obtained from Immunex, Inc. (Seattle, Wash.), was mixed with raffinose and citrate at pH 4 and 7. The mixture had a total solids content of 5 to 10 mg / mL. Excipient components represented 5 to 15% of the total solids content. Each solution was spray dried to form particles using a Buchi 190 laboratory scale drier (Buchi, Switzerland) under the following conditions: feed rate: 5 ml / min; outlet temperature: 70° C.; atomization pressure: 100 psi (0.69 MPa). The ED values of the pH 4.0 and 7.3 formulations were 71 and 66%, respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Percent by massaaaaaaaaaa
Lengthaaaaaaaaaa
Login to view more

Abstract

Methods are provided for preparing spray-dried, drug-containing particles comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining the solution and the drug and optional excipient, wherein an absolute net charge is associated with the drug and optional excipient as a result of an absolute difference between the pH and effective pI; and (c) spray drying the solution to form the spray-dried, drug-containing particles. Particles and compositions comprising the prepared particles as well as methods of use are also provided.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner NOVARTIS FARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products